HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Langer/Twincraft

This article was originally published in The Rose Sheet

Executive Summary

Medical and therapeutic skincare company Langer will expand into additional personal care categories with its acquisition of private label manufacturer Twincraft early next year, firm states in Nov. 14 release. Valued at $26.7 mil., the transaction is expected to close in the first quarter of 2007, Langer says. The acquisition of Twincraft, producer of specialty bar soap, will bring Langer into the health and beauty, amenities, mass and direct marketing channels, firm notes. The soap manufacturer grossed revenues of approximately $27.1 mil. for fiscal year 2005. For the nine months ended Sept. 30, the firm reported revenues of $20.7 mil. Twincraft President and CEO Peter Asch is expected to join Langer's board of directors. The firm employs approximately 200 people in its Winooski and Essex Junction, Vt., locations. The business is expected to remain in Vermont...

You may also be interested in...



QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

UsernamePublicRestriction

Register

RS014370

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel